An early stage clinical trial has indicated that an inhaled version of CanSino Biologics' (CanSinoBIO) (HKG:6185) COVID-19 vaccine, Ad5-nCoV, triggered immune responses without serious side effects, Reuters news agency reported on Wednesday.
According to a peer-reviewed paper, two inhaled doses of the Ad5-nCoV vaccine, given 28 days apart, elicited similar level of neutralising antibodies to those of a single injection,
These readings are based on data from a Phase I trial involving 130 healthy adult participants in China and published on the medical journal the Lancet Infectious Disease on Monday.
The inhaled vaccine did not cause serious side effects in the study, the paper said.
Authors of the paper include researchers at Academy of Military Medical Sciences, CanSino Biologics and other Chinese institutions.
The single-dose injected Ad5-nCoV vaccine is already cleared for use in China, Mexico and Pakistan, Reuters added.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial